DALLAS, Aug. 04, 2022 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), an American company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, CEO of Vaxxinity , will be presenting at the 42nd Annual Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 11, 2022 at 1:00 p.m. ET.
A live webcast of the presentation can be accessed under “Events and Presentations” in the Investors section of the Company’s website, https://ir.vaxxinity.com/events-presentations, and will be available for replay for 90 days after the presentation. ‘event. .
Vaxxinity, Inc. is a goal-oriented biotechnology company committed to democratizing healthcare worldwide. The company is pioneering a new class of synthetic peptide-based immunotherapeutic vaccines aimed at disrupting the existing treatment paradigm for chronic diseases, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration . The company’s proprietary technology platform has enabled the innovation of new pipeline candidates designed to bring vaccine efficacy to the treatment of chronic diseases, including Alzheimer’s disease, Parkinson’s disease, migraine and hypercholesterolemia. The technology is also being implemented as part of a vaccination program against COVID-19. Vaxxinity has optimized its pipeline to achieve potentially historic global impact on human health.
For more information about Vaxxinity, Inc., visit http://www.vaxxinity.com and follow us on social media @vaxxinity.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “potentially”, “will” and similar expressions, is intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on Vaxxinity’s management’s current expectations and assumptions. Forward-looking statements include statements about the development of a new class of immunotherapeutic vaccines and about the innovation and efficacy of Vaxxinity’s product candidates. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Other important factors to consider in making forward-looking statements are described in the “Risk Factors” section of the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2022 and d other reports we file with the Securities and Exchange Commission. Forward-looking statements are made as of this date, and Vaxxinity undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Copyright 2022 GlobeNewswire, Inc.